Hot AI Mandate: Germany-based Corporate Venture Capital Invests Technologies Targeting Kidney Related Diseases

1 Mar

A venture arm of the world’s leading provider of products and services for people with chronic kidney failure is headquartered in Germany. The firm has offices in USA, Germany, and Israel, and is actively seeking early-stage investment opportunities that align with Fresenius’ core businesses. Typical size of investment is around $5M, and the firm focuses on Series A to B rounds. The firm is open to global opportunities.

The firm is interested in products and technologies across therapeutics, medical devices, diagnostics, and digital health that target the following therapeutic sectors: chronic kidney disease and dialysis, intensive care medicine, cardiovascular diseases, autoimmune diseases, diabetes, and other kidney-related diseases. In terms of medical devices, the firm is open to 510k and PMA regulatory pathways.

The firm is open to working with all types of management teams. The firm can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: